THC Farmaceuticals Inc (CBDG) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of THC Farmaceuticals Inc $0.02, price $0.02, upside -12.5%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch THC Farmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0002 – $0.2943 · fair‑value band $0.0197 – $0.0230 · the $0.0240 price screens above the $0.0210 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow THC Farmaceuticals in your weekly email
Every Wednesday you see whether THC Farmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The company's machines are placed in hotels, stores, bowling alleys, and other high customer traffic areas for small and medium sized businesses.
Show more
THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The company's machines are placed in hotels, stores, bowling alleys, and other high customer traffic areas for small and medium sized businesses. As of June 30, 2015, it had a total of eight machines for public use along the Wasatch Front in the State of Utah. The company was formerly known as City Media, Inc. and changed its name to THC Farmaceuticals, Inc. in February 2015. THC Farmaceuticals, Inc. was founded in 2008 and is based in Scottsdale, Arizona. THC Farmaceuticals, Inc. operates as a subsidiary of Weed Growth Fund, Inc.
Stock analysis
THC Farmaceuticals Inc (CBDG) currently trades at $0.0240, while our model-based Fair Value estimate is $0.0210, implying the stock looks roughly 14.3% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.0210 per share, and 0 of the 5 models we run sit above the $0.0240 price.
Bear case: the Asset-Based group reads lowest at $0.0040, and 5 of the 5 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0197 (bear) to $0.0230 (bull), the price of $0.0240 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
THC Farmaceuticals Inc reported revenue of $10.0K in FY2022 versus $12.2K in FY2018, a compound −4.9%/yr. Reported net income was −$10.4K in FY2025.
Key figures
Market cap $199K · P/S ratio 10.8 · Return on equity −14.9% · Return on assets (EBIT) −0.8% · Operating margin −786% · Revenue (TTM) $18.5K · Revenue growth (YoY) +3.0% · Free cash flow $636K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 70% below its 52-week high and 823% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −13%, CBDG screens richer than that median.
Fair Value models
Bear $0.0197Fair Value $0.0210Bull $0.0230
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.21/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.0%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
’11
’12
’13
’14
’16
’17
’18
’19
’20
’22
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−56.4% (2017) → −84.9% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 7/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside−13% · Above median
Profitability
Return on assets−5% · Above median
Growth and dividend
Revenue growth3% · Above median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is THC Farmaceuticals Inc (CBDG) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0210 versus a price of $0.0240, about −13% upside (overvalued).
What is the fair value of CBDG?
Our model-based fair value for THC Farmaceuticals Inc is $0.0210 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0240.
What is the quality score of CBDG?
THC Farmaceuticals Inc has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for THC Farmaceuticals Inc (CBDG)?
Our model-based price target is the fair value of $0.0210 (as of Sep 23, 2026) from 5 valuation models. Cautious scenario $0.0197, optimistic scenario $0.0230. It is a calculation from audited fundamentals, not an analyst target.
What is the THC Farmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.0210, about −13% upside versus a price of $0.0240 (overvalued). Cautious scenario $0.0197, optimistic scenario $0.0230. The calculation is refreshed regularly with new filings.
What is the revenue of THC Farmaceuticals Inc (CBDG)?
THC Farmaceuticals Inc reported trailing-twelve-month revenue of about $18.5K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of THC Farmaceuticals Inc (CBDG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For THC Farmaceuticals Inc it is $0.0210 per share (as of Sep 23, 2026), against a price of $0.0240. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is THC Farmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CBDG trades above its calculated fair value: price $0.0240, fair value $0.0210, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CBDG?
No. The price is what the market pays today ($0.0240); the fair value is what the company's own numbers justify ($0.0210). For THC Farmaceuticals Inc the two are $0.0030 per share apart. That gap is exactly why we show both numbers side by side.
How much is THC Farmaceuticals Inc worth?
The market values THC Farmaceuticals Inc at about $199K (market capitalisation, as of Sep 23, 2026). Per share that is $0.0240; our models calculate a fair value of $0.0210 per share.
What do the bullish and bearish scenarios say about CBDG?
Our models span a range for THC Farmaceuticals Inc: cautious scenario $0.0197, base $0.0210, optimistic $0.0230 per share (as of Sep 23, 2026, price $0.0240). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of THC Farmaceuticals Inc (CBDG)?
Balance-sheet figures for THC Farmaceuticals Inc (as of Sep 23, 2026): return on equity −14.9%, debt of 0.02 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is CBDG from its 52-week high?
THC Farmaceuticals Inc trades at $0.0240, about 70% below its 52-week high of $0.0800 and 823% above the low of $0.0026 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0210 is for.
Which stocks are comparable to THC Farmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is THC Farmaceuticals Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0240, calculated fair value $0.0210 (−13%), Quality Score 63/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CBDG calculated?
We run THC Farmaceuticals Inc through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0210, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. THC Farmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of THC Farmaceuticals Inc (CBDG)?
The closing price on Sep 18, 2026 was $0.0240. Our model-based fair value is $0.0210, about −13% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with THC Farmaceuticals Inc right now?
The price sits above even our optimistic bull case ($0.0230). The favourable scenario is already priced in. Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of THC Farmaceuticals Inc
How large is the market capitalisation of THC Farmaceuticals Inc (CBDG)?
The market capitalisation of THC Farmaceuticals Inc is $199K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of THC Farmaceuticals Inc (CBDG)?
The price-to-sales ratio of THC Farmaceuticals Inc is 10.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of THC Farmaceuticals Inc (CBDG)?
The return on equity (ROE) of THC Farmaceuticals Inc is −14.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of THC Farmaceuticals Inc (CBDG)?
On an EBIT basis the return on assets of THC Farmaceuticals Inc is −0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of THC Farmaceuticals Inc (CBDG)?
The operating margin of THC Farmaceuticals Inc is −786% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at THC Farmaceuticals Inc (CBDG)?
Revenue at THC Farmaceuticals Inc is growing +3.0% versus a year earlier (3y avg −0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does THC Farmaceuticals Inc (CBDG) generate?
The free cash flow of THC Farmaceuticals Inc is $636K (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does THC Farmaceuticals Inc (CBDG) carry?
The net debt of THC Farmaceuticals Inc is $115K (fiscal year 2025, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch THC Farmaceuticals Inc in the live analysis
One click puts THC Farmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026